ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

8:30AM-10:30AM: Abstract Number: 0010

Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)

8:30AM-10:30AM: Abstract Number: 0167

Reliability of a Novel Pediatric Joint-Specific Scoring System for the Elbow, Wrist and Finger Joints

Imaging of Rheumatic Diseases Poster (0149–0182)

8:30AM-10:30AM: Abstract Number: 0304

Renal Involvement in Sjőgren’s Syndrome: Predictors and Impact on Patient Outcome

Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

8:30AM-10:30AM: Abstract Number: 0405

Retrospective Study on the Prognostic Value of Cardiac Magnetic Resonance Imaging Abnormalities in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

8:30AM-10:30AM: Abstract Number: 0115

Rheumatic Disease Management by Resilient Rheumatology Providers in COVID-19 Pandemic: A National Veterans Affairs Follow-up Survey Assessing Provider Practice and Views Since June 2020

Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM: Abstract Number: 0015

Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules

RA – Etiology & Pathogenesis Poster (0011–0045)

8:30AM-10:30AM: Abstract Number: 0253

Rheumatoid Factor Status as a Predictor of Disease Activity and Disability:An Analysis of the New CARRA Registry Polyarticular Juvenile Idiopathic Arthritis Cohort

Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)

8:30AM-10:30AM: Abstract Number: 0145

Rheumatology Provider Perspectives on Using Patient-Reported Outcomes in Clinical Care

Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

8:30AM-10:30AM: Abstract Number: 0095

Risk Factors for “Long Haul” COVID-19 in Rheumatology Outpatients in New York City

Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM: Abstract Number: 0284

Risk Factors for Dementia in Patients with Incident Rheumatoid Arthritis: A Population-based Cohort Study

RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

8:30AM-10:30AM: Abstract Number: 0285

Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment

RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

8:30AM-10:30AM: Abstract Number: 0204

Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents

Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

8:30AM-10:30AM: Abstract Number: 0111

Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study

Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM: Abstract Number: 0395

RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon

Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

8:30AM-10:30AM: Abstract Number: 0323

Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].